No­vo rais­es 2023 out­look due to high­er than ex­pect­ed Ozem­pic and We­govy sales in the US

No­vo Nordisk is rais­ing its sales and op­er­at­ing prof­it es­ti­mates for the year thanks to its di­a­betes and an­ti-obe­si­ty semaglu­tide prod­ucts We­govy and Ozem­pic, …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER